Showing results (521-530 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|August 11, 2023
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecanMing Zhao, Timothy P DiPeri, Maria Gabriela Raso, et al.
NPJ Breast Cancer|August 15, 2023
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancerZhi Ling Teo, Mark J O'Connor, Stephanie Versaci, et al.
NPJ Breast Cancer|October 19, 2023
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancerSrinivas Veerla, Lennart Hohmann, Deborah F Nacer, et al.
NPJ Breast Cancer|October 22, 2023
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysisNelson S Moss, Jolene M Singh, Anne S Reiner, et al.
NPJ Breast Cancer|October 6, 2023
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO studyNicholas C Turner, A Douglas Laird, Melinda L Telli, et al.
NPJ Breast Cancer|September 29, 2023
Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutantsAnasuya Pal, Laura Gonzalez-Malerva, Seron Eaton, et al.
NPJ Breast Cancer|September 30, 2023
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patientsMarjolijn M Ladan, Titia G Meijer, Nicole S Verkaik, et al.
NPJ Breast Cancer|July 13, 2023
Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?Jing Yu, Edaise M da Silva, Hae-Sun La, et al.
NPJ Breast Cancer|June 23, 2023
Rare subtypes of triple negative breast cancer: Current understanding and future directionsAlexandra Thomas, Jorge S Reis-Filho, Charles E Geyer, et al.
NPJ Breast Cancer|February 8, 2019
pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activationAmir Sonnenblick, David Venet, Sylvain Brohée, et al.
Pageof 98